Co-delivery of rituximab targeted curcumin and imatinib nanostructured lipid carriers in non-Hodgkin lymphoma cells

References

• Abbasalipo, R., et al., 2012. Characterization and stability of nanostructured lipid carriers as drug delivery system. Pakistan journal of biological sciences, 15 (3), 141–146.
   PubMedGoogle Scholar
• Abdollahpour-Alitappeh, M., et al., 2018. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line. Artificial cells, nanomedicine, and biotechnology, 46 (Suppl 2), 1–8.
   PubMedGoogle Scholar
• Acharya, S., and Sahoo, S.K., 2016. Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nano scavenger for inducing cytotoxicity in imatinib resistant cells. Journal of colloid and interface science, 467, 180–191.
   PubMed Web of Science ®Google Scholar
• Aggarwal, B.B., et al., 2003. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer research, 23 (1A), 363–398.
   PubMed Web of Science ®Google Scholar
• Aggarwal B.B., et al., 2007. Curcumin: biological and medicinal properties. In: P.N. Ravindran et al., eds. Turmeric: the genus Curcuma. New York, NY, USA: CRC Press, 297–368.
   Google Scholar
• Anand, P., et al., 2008. Curcumin and cancer: an “old age” disease with an “age-old” solution. Cancer Letters, 267 (1), 133–164.
   PubMed Web of Science ®Google Scholar
• Balogun, E., et al., 2003. Curcumin activates the haem oxygenase-1 gene via regulation of nrf2 and the antioxidant-responsive element. Biochemical journal, 371 (3), 887–895.
   PubMedGoogle Scholar
• Bar-Sela, G., et al., 2010. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Current medicinal chemistry, 17 (3), 190–197.
   PubMed Web of Science ®Google Scholar
• Bhandarkar, S.S., and Arbiser, J.L., 2007. Curcumin as an inhibitor of angiogenesis. Advances in Experimental medicine and biology, 595, 185–195.
   PubMed Web of Science ®Google Scholar
• Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry, 72 (1-2), 248–254.
   PubMed Web of Science ®Google Scholar
• Breccia, M., et al., 2008. Rituximab associated to imatinib for coexisting therapy-related chronic myeloid leukaemia and relapsed non-Hodgkin lymphoma. Leukemia research, 32 (2), 353–355.
   PubMed Web of Science ®Google Scholar
• Chu, Y., et al., 2017. Romidepsin alone or in combination with anti-CD20 chimeric antigen receptor expanded natural killer cells targeting Burkitt lymphoma in vitro and in immunodeficient mice. Oncoimmunology, 6 (9), e1341031.
   PubMed Web of Science ®Google Scholar
• Chute, J.P., and Himburg, H.A., 2013. Imatinib tackles lymphoma via the PDGFRβ+ pericyte. Blood, 121 (26), 5107–5108.
   PubMed Web of Science ®Google Scholar
• Cruz-Correa, M., et al., 2006. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Clinical gastroenterology and hepatology, 4 (8), 1035–1038.
   PubMed Web of Science ®Google Scholar
• Deininger, M.W., et al., 2003. Practical management of patients with chronic myeloid leukemia receiving imatinib. Journal of clinical oncology, 21 (8), 1637–1647.
   PubMed Web of Science ®Google Scholar
• Dhillon, N., et al., 2008. Phase II trial of Curcumin, an NF-κB inhibitor, in patients with advanced pancreatic cancer. Clinical cancer research, 14 (14), 4491–4499.
   PubMed Web of Science ®Google Scholar
• Duvoix, A., et al., 2005. Chemopreventive and therapeutic effects of curcumin. Cancer letters, 223 (2), 181–190.
   PubMed Web of Science ®Google Scholar
• Epstein, J., et al., 2010. Curcumin as a therapeutic agent: the evidence from in vitro, animal and human studies. British journal of nutrition, 103 (11), 1545–1557.
   PubMed Web of Science ®Google Scholar
• Friuli, V., et al., 2018. Influence of dissolution media and presence of alcohol on the in vitro performance of pharmaceutical products containing an insoluble drug. Journal of pharmaceutical sciences, 107 (1), 507–511.
   PubMed Web of Science ®Google Scholar
• Gertsch, J., et al., 2003. Curcumin differentially modulates mRNA profiles in Jurkat T and human peripheral blood mononuclear cells. Bioorganic & medicinal chemistry, 11 (6), 1057–1063.
   PubMed Web of Science ®Google Scholar
• Ghalaut, V.S., et al., 2012. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. Journal of oncology pharmacy practice, 18 (2), 186–190.
   PubMedGoogle Scholar
• Goel, A., et al., 2008. Curcumin as “curecumin”: from kitchen to clinic. Biochemical pharmacology, 75 (4), 787–809.
   PubMed Web of Science ®Google Scholar
• Gopal, P.K., et al., 2014. Curcumin induces caspase mediated apoptosis in JURKAT cells by disrupting the redox balance. Asian pacific journal of cancer prevention, 15 (1), 93–100.
   PubMedGoogle Scholar
• Guo, Y., et al., 2015. Curcumin potentiates the anti-leukemia effects of imatinib by down regulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph + acute lymphoblastic leukemia. International journal of biochemistry & cell biology, 65, 1–11.
   PubMed Web of Science ®Google Scholar
• Gupta, B., et al., 2017. Solid matrix-based lipid nano platforms as carriers for combinational therapeutics in cancer. Journal of pharmaceutical investigation, 47 (6), 461–473.
   Google Scholar
• Hatcher, H., et al., 2008. Curcumin: from ancient medicine to current clinical trials. Cellular and molecular life sciences, 65 (11), 1631–1652.
   PubMed Web of Science ®Google Scholar
• Jaiswal, P., et al., 2016. Nanostructured lipid carriers and their current application in targeted drug delivery. Artificial cells, nanomedicine, and biotechnology, 44 (1), 27–40.
   PubMed Web of Science ®Google Scholar
• Jensen, M., et al., 1998. CD20 is a molecular target for scFvFc: zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biology of blood and marrow transplantation, 4 (2), 75–83.
   PubMedGoogle Scholar
• Jurenka, J.S., 2009. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: A review of preclinical and clinical research. Alternative medicine review, 14, 141–153.
   PubMed Web of Science ®Google Scholar
• Kelkel, M., et al., 2010. Potential of the dietary antioxidants resveratrol and curcumin in prevention and treatment of hematologic malignancies. Molecules, 15 (10), 7035–7074.
   PubMed Web of Science ®Google Scholar
• Kliem, C., et al., 2012. Curcumin suppresses T cell activation by blocking Ca2+ mobilization and nuclear factor of activated T cells (NFAT) activation. Journal of biological chemistry, 287 (13), 10200–10209.
   PubMed Web of Science ®Google Scholar
• Kunnumakkara, A.B., et al., 2008. Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer letters, 269 (2), 199–225.
   PubMed Web of Science ®Google Scholar
• Kurniawan, J., et al., 2017. Interaction forces and membrane charge tunability: oleic acid containing membranes in different pH conditions. Biochimica et biophysica acta, 1859 (2), 211–217.
   Web of Science ®Google Scholar
• Lee, C.K., et al., 2011. Effects of oral curcumin on the pharmacokinetics of intravenous and oral etoposide in rats: possible role of intestinal CYP3A and P-gp inhibition by curcumin. Biopharmaceutics & drug disposition, 32 (4), 245–251.
   PubMed Web of Science ®Google Scholar
• Lyklema, J., 2003. Electrokinetics after Smoluchowski. Colloids and surfaces A: physicochemical and engineering aspects, 222 (1-3), 5–14.
   Web of Science ®Google Scholar
• Menon, V.P., and Sudheer, A.R., 2007. Antioxidant and anti-inflammatory properties of curcumin. Advances in experimental medicine and biology, 595, 105–125.
   PubMed Web of Science ®Google Scholar
• Patil, S., et al., 2015. Enhanced oral bioavailability and anticancer activity of novel curcumin loaded mixed micelles in human lung cancer cells. Phytomedicine, 22 (12), 1103–1111.
   PubMed Web of Science ®Google Scholar
• Peng, X.X., et al., 2012. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells. Chinese journal of cancer research, 31 (2), 110–118.
   Google Scholar
• Qiao, Q., et al., 2013. Curcumin enhances the response of non-Hodgkin’s lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation. Oncology reports, 29 (1), 380–386.
   PubMed Web of Science ®Google Scholar
• Reuter, S., et al., 2008. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochemical pharmacology, 76 (11), 1340–1351.
   PubMed Web of Science ®Google Scholar
• Reuter, S., et al., 2009. Effect of curcumin on nuclear factor kappa b signaling pathways in human chronic myelogenous k562 leukemia cells. Annals of the New York academy of sciences, 1171 (1), 436–447.
   PubMedGoogle Scholar
• Ruan, J., et al., 2013. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood, 121 (26), 5192–5202.
   PubMed Web of Science ®Google Scholar
• Sandur, S.K., et al., 2007. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ros-independent mechanism. Carcinogenesis, 28 (8), 1765–1773.
   PubMed Web of Science ®Google Scholar
• Shan, D., et al., 2000. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer immunology, immunotherapy, 48 (12), 673–683.
   PubMed Web of Science ®Google Scholar
• Sharma, R.A., 2004. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clinical cancer research, 10 (20), 6847–6854.
   PubMed Web of Science ®Google Scholar
• Shereen, E., et al., 2014. Spectrophotometric determination of imatinib mesylate using charge transfer complexes in pure form and pharmaceutical formulation. Chemical rapid communications, 2 (3), 1–9.
   Google Scholar
• Si, M., et al., 2013. Reversion effects of curcumin on multidrug resistance of MNNG/HOS human osteosarcoma cells in vitro and in vivo through regulation of P-glycoprotein. Chinese medical journal, 126 (21), 4116–4123.
   PubMed Web of Science ®Google Scholar
• Sikora, E., 2006. Curcumin induces caspase-3-dependent apoptotic pathway but inhibits DNA fragmentation factor 40/caspase-activated DNase endonuclease in human Jurkat cells. Molecular cancer therapeutics, 5 (4), 927–934.
   PubMed Web of Science ®Google Scholar
• Song, L., et al., 2019. Apoptosis-promoting effect of rituximab-conjugated magnetic nanoprobes on malignant lymphoma cells with CD20 overexpression. International journal of nanomedicine, 14, 921–936. ‏
   PubMed Web of Science ®Google Scholar
• Teiten, M.H., et al., 2010. Curcumin-the paradigm of a multi-target natural compound with applications in cancer prevention and treatment. Toxins, 2 (1), 128–162.
   PubMed Web of Science ®Google Scholar
• Teiten, M.H., et al., 2012. Identification of differentially expressed proteins in curcumin-treated prostate cancer cell lines. OMICS, 16 (6), 289–300.
   PubMed Web of Science ®Google Scholar
• Teiten, M.H., et al., 2009. Gene expression profiling related to anti-inflammatory properties of curcumin in k562 leukemia cells. Annals of the New York academy of sciences, 1171 (1), 391–398.
   PubMedGoogle Scholar
• Tian, C., et al., 2017. N-acetyl-L-cysteine functionalized nanostructured lipid carrier for improving oral bioavailability of curcumin: preparation, in vitro and in vivo evaluations. Drug delivery, 24 (1), 1605–1616.
   PubMed Web of Science ®Google Scholar
• Tsai, P.-C., et al., 2012. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical cancer research, 18 (4), 1039–1050.
   PubMed Web of Science ®Google Scholar
• Usmani, S.S., et al., 2017. THPdb: database of FDA-approved peptide and protein therapeutics. PLoS one, 12 (7), e0181748.
   PubMed Web of Science ®Google Scholar
• Vadhan Raj, S., et al., 2007. Curcumin down regulates NF-κB and related genes in patients with multiple myeloma: Results of a phase1/2 study. Blood, 110 (11), 1177.
   Google Scholar
• Vallianou, N.G., et al., 2015. Potential anticancer properties and mechanisms of action of curcumin. Anticancer research, 35 (2), 645–651.
   PubMed Web of Science ®Google Scholar
• Varshosaz, J., et al., 2014. Synthesis and characterization of folate-targeted dextran/retinoic acid micelles for doxorubicin delivery in acute leukemia. BioMed research international. doi: 10.1155/2014/525684
   PubMed Web of Science ®Google Scholar
• Varshosaz, J., et al., 2019. PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2. Journal of liposome research, 29, 383–398.
   PubMed Web of Science ®Google Scholar
• Wu, L.X., et al., 2014. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro. Acta pharmacologica sinica, 35 (3), 401–409.
   PubMed Web of Science ®Google Scholar
• Zhou, S., et al., 2016. Rituximab-conjugated and doxorubicin-loaded microbubbles combined with ultrasound irradiation inhibits proliferation and induces apoptosis in Raji cell lines. Oncology reports, 35 (2), 801–808.
   PubMed Web of Science ®Google Scholar